Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 3/20 | 0.57 |
| ▸ | NAAA | Q02083 | 3/20 | 0.55 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.50 |
| ▸ | MAOB | P27338 | 2/20 | 0.50 |
| ▸ | HTR3A | P46098 | 1/20 | 0.50 |
| ▸ | CCR3 | P51677 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5911061 | 0.98 | NAAA (0.58) | MIFNAAAMAOAL3MBTL1SIGMAR1 | |
| SCHEMBL920069 | 0.98 | NAAA (0.58) | MIFNAAAMAOAL3MBTL1SIGMAR1 | |
| SCHEMBL919176 | 0.93 | HTR3A (0.57) | MIFNAAAMAOAL3MBTL1SIGMAR1 | |
| SCHEMBL921157 | 0.83 | HIF1A (0.52) | MIFHTR3A | |
| SCHEMBL9819738 | 0.81 | NAAA (0.64) | MIFNAAAMAOASIGMAR1MAOB | |
| SCHEMBL9819842 | 0.81 | NAAA (0.64) | MIFNAAAMAOASIGMAR1MAOB | |
| SCHEMBL9819844 | 0.81 | NAAA (0.64) | MIFNAAAMAOASIGMAR1MAOB | |
| SCHEMBL9819781 | 0.81 | NAAA (0.64) | MIFNAAAMAOASIGMAR1MAOB | |
| SCHEMBL9819828 | 0.81 | NAAA (0.64) | MIFNAAAMAOASIGMAR1MAOB | |
| SCHEMBL9819790 | 0.81 | NAAA (0.64) | MIFNAAAMAOASIGMAR1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11033577-B2 | Polymer conjugate of hexa-coordinated platinum complex | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2021-06-15 | — | — | US | disclosed |
| EP-3395857-B1 | POLYMER CONJUGATE OF SULFOXIDE DERIVATIVE-COORDINATED PLATINUM(II) COMPLEX | NIPPON KAYAKU KK (JP) | 2021-05-26 | — | — | EP | disclosed |
| CN-108473676-B | Polymer conjugate of sulfoxide derivative coordination platinum (II) complex | 日本化药株式会社 | 2021-04-27 | — | — | CN | disclosed |
| US-10946028-B2 | Polymer conjugate of sulfoxide derivative-coordinated platinum(II) complex | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2021-03-16 | — | — | US | disclosed |
| CN-108026271-B | Polymer conjugate of 6-coordinate platinum complex | 日本化药株式会社 | 2021-03-12 | — | — | CN | disclosed |
| EP-3351580-B1 | POLYMER CONJUGATE OF HEXA-COORDINATED PLATINUM COMPLEX | NIPPON KAYAKU KK (JP) | 2021-02-24 | — | — | EP | disclosed |
| US-10596191-B2 | Polymer conjugate of hexa-coordinated platinum complex | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2020-03-24 | — | — | US | disclosed |
| US-20190282612-A1 | Polymer Conjugate Of Hexa-Coordinated Platinum Complex | NIPPON KAYAKU KK (JP) | 2019-09-19 | — | — | US | disclosed |
| US-20180369254-A1 | Polymer Conjugate Of Sulfoxide Derivative-Coordinated Platinum(II) Complex | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2018-12-27 | — | — | US | disclosed |
| EP-3395857-A1 | POLYMER CONJUGATE OF SULFOXIDE DERIVATIVE-COORDINATED PLATINUM(II) COMPLEX | Nippon Kayaku Kabushiki Kaisha (JP) | 2018-10-31 | — | — | EP | disclosed |
| EP-1589963-A1 | USE OF 10-AMINOALIPHATYL-DIBENZ B,F OXEPINES FOR THE TR EATMENT OF DEGENERATIVE OCULAR DISORDERS | Novartis AG (CH) | 2005-11-02 | — | — | EP | disclosed |
| WO-2004066993-A1 | USE OF 10-AMINOALIPHATYL-DIBENZ[B,F]OXEPINES FOR THE TREATMENT OF DEGENERATIVE OCULAR DISORDERS | NOVARTIS AG (CH) | 2004-08-12 | — | — | WO | disclosed |
| WO-2003057204-A2 | MODULATION OF IAMT (PIMT OR PCMT) IN IMMUNE SYSTEM | NORDIC BIOSCIENCE A/S (DK) | 2003-07-17 | — | — | WO | disclosed |
| US-5780501-A | ADMINISTERING TO A MAMMAL | NOVARTIS CORPORATION (US) | 1998-07-14 | — | — | US | disclosed |
| US-5780500-A | Anti-neurodegeneratively active 10-aminoaliphatyl-dibenzi b,f! oxepines | NOVARTIS CORPORATION (US) | 1998-07-14 | — | — | US | disclosed |
| WO-1997046549-A1 | ANTI-NEURODEGENERATIVELY EFFECTIVE XANTHENE DERIVATIVES | NOVARTIS AG (CH) | 1997-12-11 | — | — | WO | disclosed |
| WO-1997045422-A1 | ANTI-NEURODEGENERATIVELY EFFECTIVE 10-AMINOALIPHATYL-DIBENZ[b,f]OXEPINE SALTS | NOVARTIS AG (CH) | 1997-12-04 | — | — | WO | disclosed |
| EP-0726265-A1 | 10-Aminoaliphatyl-dibenz(b,f)oxepins with antineurodegenarative activity | CIBA-GEIGY AG (CH) | 1996-08-14 | — | — | EP | disclosed |
| US-4987132-A | PLATELET ACTIVATING FACTOR ANTAGONISTS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1991-01-22 | — | — | US | disclosed |
| EP-0279681-A2 | Saturated heterocyclic carboxamide derivatives | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1988-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10596191-B2 | Polymer conjugate of hexa-coordinated platinum complex | DCLRE1A, XPA, FPGS | MIF 2589/4885NAAA 1251/4885MAOA 4038/4885 |
| US-11033577-B2 | Polymer conjugate of hexa-coordinated platinum complex | DCLRE1A, XPA, FPGS | MIF 2589/4885NAAA 1251/4885MAOA 4038/4885 |
| US-20190282612-A1 | Polymer Conjugate Of Hexa-Coordinated Platinum Complex | DCLRE1A, XPA, FPGS | MIF 2589/4885NAAA 1251/4885MAOA 4038/4885 |
| US-10946028-B2 | Polymer conjugate of sulfoxide derivative-coordinated platinum(II) complex | FPGS, GSS, SCLY | MIF 1598/4885NAAA 3767/4885MAOA 4221/4885 |
| US-20180369254-A1 | Polymer Conjugate Of Sulfoxide Derivative-Coordinated Platinum(II) Complex | FPGS, GSS, SCLY | MIF 1598/4885NAAA 3767/4885MAOA 4221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.